Find a Clinical Trial
Filter
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
All genders
Recruiting now
Department of Medicine, Cancer Center
Tufts Medical Center
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Non-small cell lung cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Division of Thoracic Surgery
Tufts Medical Center
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Diffuse large B-cell lymphoma
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Tufts Medical Center
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
Recruiting now
Department of Medicine, Cancer Center
Tufts Medical Center
Perioperative versus adjuvant chemotherapy for pancreatic cancer
Pancreatic cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Tufts Medical Center
The ImmuneSense Study
Glioblastoma
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Tufts Medical Center
To Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Small cell lung cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Tufts Medical Center
RA-PROPR
Rheumatoid arthritis
All genders
Recruiting now
Department of Medicine, Division of Rheumatology
Tufts Medical Center
BIPI
Systemic sclerosis
All genders
Recruiting now
Department of Medicine, Division of Rheumatology
Tufts Medical Center
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Lymphomas (adult)
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Tufts Medical Center